» Articles » PMID: 38555747

Progesterone-mediated Remodeling of the Maternal-fetal Interface by a PGRMC1-dependent Mechanism

Overview
Date 2024 Mar 31
PMID 38555747
Authors
Affiliations
Soon will be listed here.
Abstract

Implantation and maintenance of pregnancy involve intricate immunological processes that enable the developing fetus to coexist with the maternal immune system. Progesterone, a critical hormone during pregnancy, is known to promote immune tolerance and prevent preterm labor. However, the mechanism by which progesterone mediates these effects remains unclear. In this study, we investigated the role of the non-classical progesterone receptor membrane component 1 (PGRMC1) in progesterone signaling at the maternal-fetal interface. Using JEG3 cells, a trophoblast model cell line, we observed that progesterone stimulation increased the expression of human leukocyte antigen-C (HLA-C) and HLA-G, key molecules involved in immune tolerance. We also found that progesterone upregulated the expression of the transcription factor ELF3, which is known to regulate trophoblast-specific HLA-C expression. Interestingly, JEG3 cells lacked expression of classical progesterone receptors (PRs) but exhibited high expression of PGRMC1, a finding we confirmed in primary trophoblasts by mining sc-RNA seq data from human placenta. To investigate the role of PGRMC1 in progesterone signaling, we used CRISPR/Cas9 technology to knockout PGRMC1 in JEG3 cells. PGRMC1-deficient cells showed a diminished response to progesterone stimulation. Furthermore, we found that the progesterone antagonist RU486 inhibited ELF3 expression in a PGRMC1-dependent manner, suggesting that RU486 acts as a progesterone antagonist by competing for receptor binding. Additionally, we found that RU486 inhibited cell invasion, an important process for successful pregnancy, and this inhibitory effect was dependent on PGRMC1. Our findings highlight the crucial role of PGRMC1 in mediating the immunoregulatory effects of progesterone at the maternal-fetal interface.

Citing Articles

Multi-Layered Mechanisms of Immunological Tolerance at the Maternal-Fetal Interface.

Joo J, Lee D, Hong J Immune Netw. 2024; 24(4):e30.

PMID: 39246621 PMC: 11377946. DOI: 10.4110/in.2024.24.e30.

References
1.
MAHAJAN D, London S . Mifepristone (RU486): a review. Fertil Steril. 1998; 68(6):967-76. DOI: 10.1016/s0015-0282(97)00189-1. View

2.
Vento-Tormo R, Efremova M, Botting R, Turco M, Vento-Tormo M, Meyer K . Single-cell reconstruction of the early maternal-fetal interface in humans. Nature. 2018; 563(7731):347-353. PMC: 7612850. DOI: 10.1038/s41586-018-0698-6. View

3.
Li Q, Meissner T, Wang F, Du Z, Ma S, Kshirsagar S . ELF3 activated by a superenhancer and an autoregulatory feedback loop is required for high-level HLA-C expression on extravillous trophoblasts. Proc Natl Acad Sci U S A. 2021; 118(9). PMC: 7936349. DOI: 10.1073/pnas.2025512118. View

4.
Wang J, Chen Z, Chen H, Wang M, Kong X, Wang Y . Elf3 drives β-catenin transactivation and associates with poor prognosis in colorectal cancer. Cell Death Dis. 2014; 5:e1263. PMC: 4047871. DOI: 10.1038/cddis.2014.206. View

5.
Zachariades E, Mparmpakas D, Pang Y, Rand-Weaver M, Thomas P, Karteris E . Changes in placental progesterone receptors in term and preterm labour. Placenta. 2012; 33(5):367-72. DOI: 10.1016/j.placenta.2012.01.002. View